Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation / Enise Ceran, Sonia Jaramillo, Anne Kathrin Merbach, Christian Rohde, Maxi Wass, Judith Schaffrath, Robert Durruthy-Durruthy, Marc Arribas-Layton, Adam Sciambi, Kathrin Rieger, Axel Nogai, Mathias Hänel, Regina Theresia Herbst, Friedrich Stölzel, Christoph Röllig, Edgar Jost, Richard Schlenk, Michelle Lotze, Richard Noppeney, Christian H. Brandts, Utz Krug, Katharina S. Götze, Sebastian Buske, Axel Florschütz, Jörg Ernst Albert Schubert, Bernhard Opitz, Eva Esseling, Stephan von Witzendorff, Marion Subklewe, Martin Kaufmann, Norbert Frickhofen, Christian W. Scholz, Kerstin Schäfer-Eckart, Volker Kunzmann, Martin Schmidt-Hieber, Herbert G. Sayer, Andreas Rank, Philipp Georg Hemmati, Frank Schüler, Marina Scheller, Simone Kowoll, Jörg Steighardt, Bayram Edemir, Beatrice Ludwig-Kraus, Lutz P. Mueller, Sabine Edemir, Abi Vainstein-Haras, Ella Sorani, Irit Gliko-Kabir, Shaul Kadosh, Sigal Tavor, Cora Gromann, Andreas Wienke, Marcus Bauer, Claudia Wickenhauser, Claudia D. Baldus, Uwe Platzbecker, Adelheid Cerwenka, Hubert Serve, Martin Bornhäuser, Christian Junghanss, Carsten Müller-Tidow

Related documents

• Cell-Based Therapy for White Matter Repair in Periventricular Leukomalacia#992296
• QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC#845541
• Bone Marrow Stromal Cells for Inflammatory Bowel Diseases#969793
• B Cell Differentiation in MS#1093318
• ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial#881671